cheiron study: docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patie...
Published 5 years ago • 213 plays • Length 4:17Download video MP4
Download video MP3
Similar videos
-
3:44
updates from the cheiron study: docetaxel plus enzalutamide for mcrpc
-
4:50
interview with dr. caffo
-
5:49
adt plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: systemic review
-
6:10
emerging management of metastatic castration-sensitive prostate cancer: front-line chemotherapy ...
-
1:19
role of the addition of docetaxel to adt in mhspc
-
1:57
enzalutamide after docetaxel for mcrpc: evaluation by the italian named patient program
-
55:35
is there still a role for docetaxel in mhspc?
-
1:37
dr. caffo discusses enzalutamide/docetaxel combination in frontline mcrpc
-
3:38
enzalutamide as treatment for men with mhspc who have received testosterone suppression
-
11:48
adding enzalutamide to standard first-line treatment improves survival for hormone-sensitive pro...
-
19:51
metastatic prostate cancer - interpreting negative trial results
-
2:09
dr. patel on early treatment with docetaxel for metastatic prostate cancer
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
8:12
the use of abiraterone and enzalutamide against crpc
-
9:28
initiation and reintroduction of docetaxel
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
25:31
management of advanced hormone-sensitive and castration-resistant prostate cancer